The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 30, 2014
Filed:
Sep. 28, 2012
Vertex Pharmaceuticals Incorporated, Cambridge, MA (US);
Jean-Damien Charrier, Wantage, GB;
Pierre-Henri Storck, Abingdon, GB;
John Studley, Witney, GB;
Francoise Yvonne Theodora Marie Pierard, Abingdon, GB;
Steven John Durrant, Abingdon, GB;
Benjamin Joseph Littler, Carlsbad, CA (US);
Paul Angell, Carlsbad, CA (US);
Robert Michael Hughes, San Diego, CA (US);
David Andrew Siesel, San Diego, CA (US);
Armando Urbina, San Diego, CA (US);
Carl Zwicker, Brighton, MA (US);
Nicholas LoConte, Winthrop, MA (US);
Timothy E. Barder, Arlington, MA (US);
Vertex Pharmaceuticals Incorporated, Boston, MA (US);
Abstract
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-1: wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.